Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02225912 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers
A Phase 4 study of Upper Respiratory Infections, sponsored by BioHealth Technologies.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Study locations
NCT02225912 is a Phase 4 study of Upper Respiratory Infections that has completed, run by BioHealth Technologies. The trial reports 6 study locations across 1 state.
The verdict
NCT02225912, a Phase 4 study of Upper Respiratory Infections, has completed, sponsored by BioHealth Technologies.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6
- Study locations
Study Summary
The hypothesis was to establish whether the use of PrevinC administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in child day care centers.
Conditions Studied
Interventions
- DRUG placebo
- OTHER PrevinC
Study Locations (6)
Florida
- Sunflower Preschool & Day Care - Hialeah
- Sunflower Preschool Childcare - Miami
- Sunflowers Academy - Miami
- Sunflowers Academy - Miami
- Sunflowers Preschool Childcare - Miami
- Mt Sinai Day Care - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-02 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02225912
The ClinicalTrials.gov registry entry for NCT02225912 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is BioHealth Technologies, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Upper Respiratory Infections appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02225912 reports 6 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02225912 about?
NCT02225912 is a clinical study titled "A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers". The hypothesis was to establish whether the use of PrevinC administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in child day care centers.
What is the current status of trial NCT02225912?
This trial is currently completed. It is a Phase 4 study. The study started on 2005-02. Estimated completion is 2005-05.
What conditions does trial NCT02225912 study?
This clinical trial studies the following conditions: Upper Respiratory Infections.
What interventions are being tested in trial NCT02225912?
The interventions under investigation include: placebo (DRUG), PrevinC (OTHER).
Who is sponsoring clinical trial NCT02225912?
This trial is sponsored by BioHealth Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02225912 being conducted?
This trial has 6 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.